Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known (angiographically documented) CAD.~* On maintenance treatment with aspirin (81 mg per day) for at least 1-month as per standard of care.~* Type 2 DM on treatment with oral hypoglycemic agents and/or insulin.~* Age between 18 and 74 years old.~Exclusion Criteria:~* History of stroke, transient ischemic attack or intracranial bleeding.~* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor).~* Known allergies to aspirin, ticlopidine, clopidogrel, prasugrel, ticagrelor.~* Weight \<60kg.~* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran).~* Blood dyscrasia or bleeding diathesis.~* Platelet count \<80x106/mL.~* Hemoglobin \<10 g/dL.~* Active bleeding or hemodynamic instability.~* Creatinine Clearance \<30 mL/minute.~* Baseline ALT \>2.5 times the upper limit of normal.~* Hb A1c ≥ 10 mg/dL within 3 months.~* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.~* Drugs interfering CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~* Pregnant females\*.~  * Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel first, then ticagrelor (Type: ACTIVE_COMPARATOR): Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
- Ticagrelor first, then prasugrel (Type: ACTIVE_COMPARATOR): Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.

Based on this trial design, predict the completion outcome and termination type (if applicable).